EP3250187A1 - Pharmaceutical compositions and plant protection agents containing oxygen-enriched vegetable oils or fatty acids - Google Patents
Pharmaceutical compositions and plant protection agents containing oxygen-enriched vegetable oils or fatty acidsInfo
- Publication number
- EP3250187A1 EP3250187A1 EP16702912.3A EP16702912A EP3250187A1 EP 3250187 A1 EP3250187 A1 EP 3250187A1 EP 16702912 A EP16702912 A EP 16702912A EP 3250187 A1 EP3250187 A1 EP 3250187A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- pharmaceutical composition
- fatty acid
- unsaturated fatty
- derivative
- glycerol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 226
- 239000011814 protection agent Substances 0.000 title claims abstract description 117
- 235000015112 vegetable and seed oil Nutrition 0.000 title claims abstract description 86
- 239000008158 vegetable oil Substances 0.000 title claims abstract description 86
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 title claims abstract description 82
- 239000001301 oxygen Substances 0.000 title claims abstract description 82
- 229910052760 oxygen Inorganic materials 0.000 title claims abstract description 82
- 235000014113 dietary fatty acids Nutrition 0.000 title description 18
- 239000000194 fatty acid Substances 0.000 title description 18
- 229930195729 fatty acid Natural products 0.000 title description 18
- 150000004665 fatty acids Chemical class 0.000 title description 18
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims abstract description 180
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims abstract description 179
- 238000011282 treatment Methods 0.000 claims abstract description 110
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 105
- 201000010099 disease Diseases 0.000 claims abstract description 102
- 210000000078 claw Anatomy 0.000 claims abstract description 51
- 241001465754 Metazoa Species 0.000 claims abstract description 45
- 210000000481 breast Anatomy 0.000 claims abstract description 43
- 230000004054 inflammatory process Effects 0.000 claims abstract description 15
- 206010061218 Inflammation Diseases 0.000 claims abstract description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 187
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 100
- 235000011187 glycerol Nutrition 0.000 claims description 65
- 239000000203 mixture Substances 0.000 claims description 62
- 239000005642 Oleic acid Substances 0.000 claims description 42
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 42
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 41
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 41
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 41
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 41
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 41
- 150000002314 glycerols Chemical class 0.000 claims description 37
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 30
- 239000004476 plant protection product Substances 0.000 claims description 13
- 239000000126 substance Substances 0.000 claims description 13
- WURFKUQACINBSI-UHFFFAOYSA-M ozonide Chemical compound [O]O[O-] WURFKUQACINBSI-UHFFFAOYSA-M 0.000 claims description 10
- 241000283690 Bos taurus Species 0.000 claims description 9
- 239000000589 Siderophore Substances 0.000 claims description 9
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 9
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 9
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 9
- JFMGYULNQJPJCY-UHFFFAOYSA-N 4-(hydroxymethyl)-1,3-dioxolan-2-one Chemical compound OCC1COC(=O)O1 JFMGYULNQJPJCY-UHFFFAOYSA-N 0.000 claims description 6
- -1 glycerol formal Chemical compound 0.000 claims description 6
- 229940074076 glycerol formal Drugs 0.000 claims description 6
- 229940100657 nasal ointment Drugs 0.000 claims description 6
- 239000007922 nasal spray Substances 0.000 claims description 6
- 229940097496 nasal spray Drugs 0.000 claims description 6
- RNVYQYLELCKWAN-UHFFFAOYSA-N solketal Chemical compound CC1(C)OCC(CO)O1 RNVYQYLELCKWAN-UHFFFAOYSA-N 0.000 claims description 5
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 230000002500 effect on skin Effects 0.000 claims 1
- 230000001459 mortal effect Effects 0.000 claims 1
- 125000005314 unsaturated fatty acid group Chemical group 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 39
- 238000000034 method Methods 0.000 abstract description 16
- 230000001580 bacterial effect Effects 0.000 abstract description 15
- 230000003612 virological effect Effects 0.000 abstract description 11
- 208000031888 Mycoses Diseases 0.000 abstract description 5
- 208000031295 Animal disease Diseases 0.000 abstract description 2
- 208000006413 Digital Dermatitis Diseases 0.000 abstract 1
- 208000023867 digital dermatitis in cattle Diseases 0.000 abstract 1
- 241000196324 Embryophyta Species 0.000 description 82
- 210000003491 skin Anatomy 0.000 description 48
- 239000002502 liposome Substances 0.000 description 31
- 239000000243 solution Substances 0.000 description 21
- 150000003904 phospholipids Chemical class 0.000 description 19
- 239000002904 solvent Substances 0.000 description 17
- 239000010410 layer Substances 0.000 description 16
- 239000002775 capsule Substances 0.000 description 15
- 208000015181 infectious disease Diseases 0.000 description 15
- 239000004480 active ingredient Substances 0.000 description 13
- 239000003921 oil Substances 0.000 description 12
- 235000019198 oils Nutrition 0.000 description 12
- 206010052428 Wound Diseases 0.000 description 11
- 208000027418 Wounds and injury Diseases 0.000 description 11
- 239000002674 ointment Substances 0.000 description 11
- 239000003960 organic solvent Substances 0.000 description 11
- 239000000575 pesticide Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 230000000844 anti-bacterial effect Effects 0.000 description 9
- 239000012876 carrier material Substances 0.000 description 9
- 239000011248 coating agent Substances 0.000 description 9
- 238000000576 coating method Methods 0.000 description 9
- 239000003094 microcapsule Substances 0.000 description 9
- 239000012188 paraffin wax Substances 0.000 description 9
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 8
- 241000233866 Fungi Species 0.000 description 7
- 229920000331 Polyhydroxybutyrate Polymers 0.000 description 7
- 244000052616 bacterial pathogen Species 0.000 description 7
- 239000006071 cream Substances 0.000 description 7
- 239000005015 poly(hydroxybutyrate) Substances 0.000 description 7
- 241001124076 Aphididae Species 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 238000006385 ozonation reaction Methods 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 239000011505 plaster Substances 0.000 description 6
- 239000007921 spray Substances 0.000 description 6
- 238000005507 spraying Methods 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 235000010469 Glycine max Nutrition 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 239000002781 deodorant agent Substances 0.000 description 5
- 238000005538 encapsulation Methods 0.000 description 5
- 230000002538 fungal effect Effects 0.000 description 5
- 210000000936 intestine Anatomy 0.000 description 5
- 239000006210 lotion Substances 0.000 description 5
- 239000004006 olive oil Substances 0.000 description 5
- 235000008390 olive oil Nutrition 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 239000002453 shampoo Substances 0.000 description 5
- 239000000344 soap Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 description 5
- 150000003626 triacylglycerols Chemical class 0.000 description 5
- 239000006216 vaginal suppository Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 241000233654 Oomycetes Species 0.000 description 4
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 4
- 208000004210 Pressure Ulcer Diseases 0.000 description 4
- 235000019484 Rapeseed oil Nutrition 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000002745 absorbent Effects 0.000 description 4
- 239000002250 absorbent Substances 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 206010000496 acne Diseases 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 239000012790 adhesive layer Substances 0.000 description 4
- 230000000843 anti-fungal effect Effects 0.000 description 4
- 230000000845 anti-microbial effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 239000002353 niosome Substances 0.000 description 4
- 150000002978 peroxides Chemical class 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 210000000813 small intestine Anatomy 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 208000002874 Acne Vulgaris Diseases 0.000 description 3
- 206010002515 Animal bite Diseases 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 241000589968 Borrelia Species 0.000 description 3
- 241000589972 Borrelia sp. Species 0.000 description 3
- 241001112696 Clostridia Species 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 206010017533 Fungal infection Diseases 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 208000016604 Lyme disease Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 3
- 240000000513 Santalum album Species 0.000 description 3
- 235000008632 Santalum album Nutrition 0.000 description 3
- 208000000260 Warts Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 230000000855 fungicidal effect Effects 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 201000010153 skin papilloma Diseases 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 235000013311 vegetables Nutrition 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- YWWVWXASSLXJHU-AATRIKPKSA-N (9E)-tetradecenoic acid Chemical compound CCCC\C=C\CCCCCCCC(O)=O YWWVWXASSLXJHU-AATRIKPKSA-N 0.000 description 2
- FABAOYOFJNAVHB-KVVVOXFISA-N (z)-octadec-9-enoic acid;propane-1,2,3-triol Chemical class OCC(O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O FABAOYOFJNAVHB-KVVVOXFISA-N 0.000 description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 2
- 241000606161 Chlamydia Species 0.000 description 2
- 241001495184 Chlamydia sp. Species 0.000 description 2
- 241000193163 Clostridioides difficile Species 0.000 description 2
- 208000001840 Dandruff Diseases 0.000 description 2
- 206010011985 Decubitus ulcer Diseases 0.000 description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
- 241001495410 Enterococcus sp. Species 0.000 description 2
- 206010017711 Gangrene Diseases 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 206010061217 Infestation Diseases 0.000 description 2
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 2
- 241001480037 Microsporum Species 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- 235000019482 Palm oil Nutrition 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- 241001521757 Propionibacterium sp. Species 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 241001147693 Staphylococcus sp. Species 0.000 description 2
- 241000194022 Streptococcus sp. Species 0.000 description 2
- 241000223238 Trichophyton Species 0.000 description 2
- 241000591119 Trichophyton sp. Species 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003899 bactericide agent Substances 0.000 description 2
- 229920000229 biodegradable polyester Polymers 0.000 description 2
- 239000004622 biodegradable polyester Substances 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 239000011258 core-shell material Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000007854 depigmenting agent Substances 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000417 fungicide Substances 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 239000004922 lacquer Substances 0.000 description 2
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 2
- 229960005287 lincomycin Drugs 0.000 description 2
- 239000000944 linseed oil Substances 0.000 description 2
- 235000021388 linseed oil Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- QYDYPVFESGNLHU-KHPPLWFESA-N methyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC QYDYPVFESGNLHU-KHPPLWFESA-N 0.000 description 2
- 239000005022 packaging material Substances 0.000 description 2
- 239000002540 palm oil Substances 0.000 description 2
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 239000003961 penetration enhancing agent Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 235000020238 sunflower seed Nutrition 0.000 description 2
- 239000010677 tea tree oil Substances 0.000 description 2
- 229940111630 tea tree oil Drugs 0.000 description 2
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 2
- 201000004647 tinea pedis Diseases 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 2
- 239000002966 varnish Substances 0.000 description 2
- 239000012873 virucide Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- BITHHVVYSMSWAG-KTKRTIGZSA-N (11Z)-icos-11-enoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCC(O)=O BITHHVVYSMSWAG-KTKRTIGZSA-N 0.000 description 1
- DQGMPXYVZZCNDQ-KBPWROHVSA-N (8E,10E,12Z)-octadecatrienoic acid Chemical compound CCCCC\C=C/C=C/C=C/CCCCCCC(O)=O DQGMPXYVZZCNDQ-KBPWROHVSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- NGYMOTOXXHCHOC-UHFFFAOYSA-N 3-methyl-5-(2,2,3-trimethylcyclopent-3-en-1-yl)pentan-2-ol Chemical compound CC(O)C(C)CCC1CC=C(C)C1(C)C NGYMOTOXXHCHOC-UHFFFAOYSA-N 0.000 description 1
- FPAQLJHSZVFKES-UHFFFAOYSA-N 5-Eicosenoic acid Natural products CCCCCCCCCCCCCCC=CCCCC(O)=O FPAQLJHSZVFKES-UHFFFAOYSA-N 0.000 description 1
- JLCXTTXSLOWJBH-UHFFFAOYSA-N 8-(5-octyl-1,2,4-trioxolan-3-yl)octanoic acid Chemical compound CCCCCCCCC1OOC(CCCCCCCC(O)=O)O1 JLCXTTXSLOWJBH-UHFFFAOYSA-N 0.000 description 1
- YWWVWXASSLXJHU-UHFFFAOYSA-N 9E-tetradecenoic acid Natural products CCCCC=CCCCCCCCC(O)=O YWWVWXASSLXJHU-UHFFFAOYSA-N 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 208000025978 Athletic injury Diseases 0.000 description 1
- 241000589969 Borreliella burgdorferi Species 0.000 description 1
- 241000282817 Bovidae Species 0.000 description 1
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 description 1
- DQGMPXYVZZCNDQ-UVZPLDOLSA-N Calendinsaeure Natural products CCCCCC=C/C=C/C=C/CCCCCCC(=O)O DQGMPXYVZZCNDQ-UVZPLDOLSA-N 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000252852 Campylobacter faecalis Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 241001185363 Chlamydiae Species 0.000 description 1
- 239000004099 Chlortetracycline Substances 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000193466 Clostridium septicum Species 0.000 description 1
- 241000193464 Clostridium sp. Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 235000015001 Cucumis melo var inodorus Nutrition 0.000 description 1
- 240000002495 Cucumis melo var. inodorus Species 0.000 description 1
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- 208000008960 Diabetic foot Diseases 0.000 description 1
- 241000605721 Dichelobacter nodosus Species 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 231100000948 EpiDerm Skin Irritation Test Toxicity 0.000 description 1
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 description 1
- 235000014066 European mistletoe Nutrition 0.000 description 1
- 241000605952 Fusobacterium necrophorum Species 0.000 description 1
- 241000282816 Giraffa camelopardalis Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 102000008133 Iron-Binding Proteins Human genes 0.000 description 1
- 108010035210 Iron-Binding Proteins Proteins 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 229930183781 Mycobactin Natural products 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 208000010195 Onychomycosis Diseases 0.000 description 1
- 235000021319 Palmitoleic acid Nutrition 0.000 description 1
- 208000005888 Periodontal Pocket Diseases 0.000 description 1
- 241000233679 Peronosporaceae Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000083879 Polyommatus icarus Species 0.000 description 1
- 229920005830 Polyurethane Foam Polymers 0.000 description 1
- 241001135239 Porphyromonas levii Species 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 244000152640 Rhipsalis cassutha Species 0.000 description 1
- 235000012300 Rhipsalis cassutha Nutrition 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 241000589970 Spirochaetales Species 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241000191984 Staphylococcus haemolyticus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 208000004374 Tick Bites Diseases 0.000 description 1
- 241000589886 Treponema Species 0.000 description 1
- 241001619548 Treponema brennaborense Species 0.000 description 1
- 241000589892 Treponema denticola Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- HQYXQBFMMYIDEA-UHFFFAOYSA-N [3-[(1-hydroxy-2-oxoazepan-3-yl)amino]-3-oxopropyl] 7-[formyl(hydroxy)amino]-2-[[2-(2-hydroxyphenyl)-4,5-dihydro-1,3-oxazole-4-carbonyl]amino]heptanoate Chemical compound ON(CCCCCC(NC(=O)C1COC(=N1)c1ccccc1O)C(=O)OCCC(=O)NC1CCCCN(O)C1=O)C=O HQYXQBFMMYIDEA-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 241001148470 aerobic bacillus Species 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 235000013532 brandy Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- KJDZDTDNIULJBE-QXMHVHEDSA-N cetoleic acid Chemical compound CCCCCCCCCC\C=C/CCCCCCCCCC(O)=O KJDZDTDNIULJBE-QXMHVHEDSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
- 229960004475 chlortetracycline Drugs 0.000 description 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 1
- 238000005253 cladding Methods 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 210000000613 ear canal Anatomy 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- QYDYPVFESGNLHU-UHFFFAOYSA-N elaidic acid methyl ester Natural products CCCCCCCCC=CCCCCCCCC(=O)OC QYDYPVFESGNLHU-UHFFFAOYSA-N 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019387 fatty acid methyl ester Nutrition 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 210000004904 fingernail bed Anatomy 0.000 description 1
- 230000001408 fungistatic effect Effects 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000000003 hoof Anatomy 0.000 description 1
- 231100000058 in vitro skin irritation / corrosion testing Toxicity 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
- 229960004963 mesalazine Drugs 0.000 description 1
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 150000004702 methyl esters Chemical group 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229940016409 methylsulfonylmethane Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000003232 mucoadhesive effect Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000006272 natural pesticide Substances 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 150000002888 oleic acid derivatives Chemical class 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 238000005949 ozonolysis reaction Methods 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920006255 plastic film Polymers 0.000 description 1
- 239000005014 poly(hydroxyalkanoate) Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000903 polyhydroxyalkanoate Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- DPBVJRXPSXTHOL-UHFFFAOYSA-N propyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCCC DPBVJRXPSXTHOL-UHFFFAOYSA-N 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 239000005871 repellent Substances 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- WBHHMMIMDMUBKC-XLNAKTSKSA-N ricinelaidic acid Chemical compound CCCCCC[C@@H](O)C\C=C\CCCCCCCC(O)=O WBHHMMIMDMUBKC-XLNAKTSKSA-N 0.000 description 1
- 229960003656 ricinoleic acid Drugs 0.000 description 1
- FEUQNCSVHBHROZ-UHFFFAOYSA-N ricinoleic acid Natural products CCCCCCC(O[Si](C)(C)C)CC=CCCCCCCCC(=O)OC FEUQNCSVHBHROZ-UHFFFAOYSA-N 0.000 description 1
- 239000012487 rinsing solution Substances 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 125000005457 triglyceride group Chemical group 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003253 viricidal effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
Definitions
- Oxygen enriched vegetable oils or fatty acids Oxygen enriched vegetable oils or fatty acids
- the present invention relates to pharmaceutical compositions, medical preparations, veterinary preparations and crop protection agents containing at least one unsaturated fatty acid or a derivative thereof or containing a vegetable oil, wherein the at least one unsaturated fatty acid or the derivative thereof or the vegetable oil is oxygenated.
- the invention also relates to a wide variety of products containing a pharmaceutical composition according to the invention, as well as various uses of the pharmaceutical composition, in particular for the treatment of viral, bacterial and / or mycotic diseases and for inhibiting inflammation.
- the invention also relates to the use of the pharmaceutical composition in the treatment of animal diseases, in particular mammalian diseases, in particular diseases of the claws or udders of animals, for example the Mortellaro disease, and corresponding processes.
- ozonated vegetable oils for example ozonated olive oil
- rizol, ie a 1,2,4-trioxolane (ozonide) in the triglyceride chains of olive oil and castor oil 2004 021 089 Ul, DE 199 32 570 Al and DE 10 2009 034 308 Al describe the use of ozonated vegetable oils in the treatment of inflammatory processes in the mouth and tooth area.
- ozonated vegetable oils known from the prior art are often insufficient in their antimicrobial action.
- not all types of infection can be treated, as ozonated vegetable oil is ineffective against certain bacteria and plants.
- their usefulness in pharmaceutical products is limited in the ozonated vegetable oils by their presence as anhydrous viscous oils.
- their use is limited to certain dosage forms, for example, preparations for treatment in the tooth area.
- Ozonized fatty acids dissolved in DMSO are known from WO 2013/1531 11 A1. The DMSO not only serves as a solvent, but also to facilitate and accelerate the transfer of fatty acids through the skin.
- the technical problem underlying the present invention is the provision of antimicrobial compositions that are improved in their effectiveness and / or applicability over the prior art.
- the technical problem underlying the present invention is also to provide pharmaceutical compositions with improved consistency.
- the technical problem underlying the present invention is also to provide pharmaceutical compositions having improved activity against certain bacteria and fungal species.
- the technical problem underlying the present invention is also to provide pharmaceutical compositions which are useful not only against bacterial and mycotic diseases, in particular inflammation, but also against viral diseases.
- the invention solves the underlying technical problem by providing a pharmaceutical composition according to claim 1.
- the invention solves the underlying technical problem by a composition, in particular pharmaceutical composition or crop protection agent containing a vegetable oil or an unsaturated fatty acid or a derivative thereof and containing a solvent, in particular glycerol or a glycerol derivative, paraffin or tertiary butanol, wherein the vegetable oil or the unsaturated fatty acid or derivative thereof is oxygenated.
- a composition in particular pharmaceutical composition or crop protection agent containing a vegetable oil or an unsaturated fatty acid or a derivative thereof and containing a solvent, in particular glycerol or a glycerol derivative, paraffin or tertiary butanol, wherein the vegetable oil or the unsaturated fatty acid or derivative thereof is oxygenated.
- the invention solves the underlying technical problem by a composition, in particular pharmaceutical composition or crop protection agent containing a vegetable oil or an unsaturated fatty acid or a derivative thereof as active ingredient and preferably containing a drug carrier, in particular a pharmaceutically acceptable carrier, wherein the vegetable oil or unsaturated fatty acid or derivative thereof is oxygenated.
- the drug carrier may be solid, gel, semi-solid, semi-liquid or liquid.
- PHB polyhydroxybutyrate
- the invention solves the underlying technical problem by a pharmaceutical composition
- a pharmaceutical composition comprising a vegetable oil or an unsaturated fatty acid or a derivative thereof and containing glycerol or a glycerol derivative, paraffin or tertiary Butanol, wherein the vegetable oil or the unsaturated fatty acid or Derivative of this is enriched with oxygen.
- the invention solves the underlying technical problem by a pharmaceutical composition
- a pharmaceutical composition comprising an unsaturated fatty acid or a derivative thereof and containing glycerol or a glycerol derivative, paraffin or tertiary butanol, wherein the unsaturated fatty acid or the derivative thereof is enriched with oxygen
- the oxygenated unsaturated fatty acid is an ozonide.
- the oxygenated unsaturated fatty acid is oleic acid.
- the composition preferably contains glycerol and / or contains a glycerol derivative selected from the group consisting of 2,3-0-isopropylidene-glycerol, glycerol formal, glycerol carbonate and mixtures thereof.
- the composition additionally contains at least one siderophore.
- the composition is contained in microencapsulated form.
- the composition is contained in liposomes.
- a pharmaceutical composition according to the invention contains no DMSO as solvent, in particular DMSO at most in traces, more preferably no DMSO.
- a pharmaceutical composition of the invention may contain a surfactant.
- surfactants suitable for pharmaceutical compositions are known to the person skilled in the art, for example Tween.
- Another technical problem underlying the invention is the provision of new fields of application and forms of use for oxygenated vegetable oils and fatty acids.
- the invention solves this underlying technical problem also by providing a plant protection product according to claim 7.
- the invention solves this underlying technical problem, in particular by providing a crop protection agent containing a vegetable oil or an unsaturated fatty acid or a derivative thereof, wherein the vegetable oil or the unsaturated fatty acid or the derivative thereof is enriched with oxygen.
- the oxygen-enriched unsaturated fatty acid is an ozonide and the crop protection agent additionally contains glycerol, a glycerol derivative, polyvinylpyrrolidone (PVP), paraffin, tertiary butanol and / or DMSO.
- the crop protection agent contains a surfactant in addition to the vegetable oil or the unsaturated fatty acid or the derivative thereof.
- the invention solves this underlying technical problem in particular by the provision of a plant protection product containing an unsaturated fatty acid or a derivative thereof, wherein the unsaturated fatty acid or the derivative thereof is enriched with oxygen.
- the oxygen-enriched unsaturated fatty acid is an ozonide and the crop protection agent additionally contains glycerol, a glycerol derivative, polyvinylpyrrolidone (PVP), paraffin, tertiary butanol and / or DMSO.
- the crop protection agent additionally contains at least one siderophore.
- the plant protection agent is preferably contained in microencapsulated form.
- the plant protection agent is preferably contained in liposomes.
- the invention solves this underlying technical problem also by a pharmaceutical composition
- a pharmaceutical composition comprising a vegetable oil or an unsaturated fatty acid or a derivative thereof, wherein the vegetable oil or the unsaturated fatty acid or the derivative thereof is oxygenated, for use according to claim 10.
- the invention solves this underlying technical problem also by a pharmaceutical composition containing a plant or an unsaturated fatty acid or a derivative thereof, wherein the vegetable oil or the unsaturated fatty acid or derivative thereof is oxygenated for use in the treatment of animals , in particular mammals, in particular of claw diseases or udder diseases in animals.
- the invention solves this underlying technical problem also by a pharmaceutical composition comprising an unsaturated fatty acid or a derivative thereof, wherein the unsaturated fatty acid or the derivative of which is oxygenated for use in the treatment of claw diseases or udder diseases in animals.
- Preferred is a pharmaceutical composition disclosed herein for use in the treatment of claw diseases or udder diseases in animals.
- the oxygenated unsaturated fatty acid is an ozonide and the pharmaceutical composition additionally contains glycerin, a glycerin derivative, tertiary butanol, paraffin and / or DMSO.
- the present invention also relates to vaginal suppositories containing a pharmaceutical composition according to the invention.
- the present invention also relates to medical wound dressing or patch containing a pharmaceutical composition of the invention.
- the present invention also relates to a paste, ointment, rinse or solution containing a pharmaceutical composition according to the invention.
- the present invention also relates to a gel or varnish comprising a pharmaceutical composition according to the invention.
- the present invention also relates to a deodorant, a soap, cream, lotion or a shampoo containing a pharmaceutical composition according to the invention.
- the present invention also relates to a diaper or panty liner containing a pharmaceutical composition of the invention.
- the present invention also relates to a capsule containing a pharmaceutical composition according to the invention, wherein the capsule is preferably a capsule which dissolves only in the intestine, in particular small intestine.
- the capsule is a microcapsule.
- the present invention also relates to a medical preparation in which a pharmaceutical composition according to the invention is applied to a carrier material based on vegetable and / or plastic, and which is provided with a polymeric coating or a coating of a natural or synthetic wax, wherein the carrier material and the coating is substantially biodegradable.
- the present invention also relates to a medical preparation in which a pharmaceutical composition according to the invention is applied to a carrier material, wherein the carrier material is a sponge or a hydrogel.
- the present invention also relates to a pharmaceutical composition of the invention for use in the treatment of viral, bacterial and / or mycotic diseases, which is preferably an anaerobic microorganism.
- the present invention also relates to a pharmaceutical composition according to the invention for use in the treatment of viral, bacterial and / or mycotic diseases, wherein it is preferred Borrelia sp., Enterococcus sp., Streptococcus sp., Staphylococcus sp., Propionibacterium sp., Chlamydia sp., Trichophyton sp., Candida sp., Microsporum sp., Oomycetes, herpes simplex viruses and / or TBE viruses.
- the present invention also relates to a pharmaceutical composition or capsule according to the invention for use in the treatment of disease by clostridia.
- the present invention also relates to a pharmaceutical composition of the invention for use in the treatment of urogenital tract and / or anal site disease.
- the present invention also relates to a pharmaceutical composition according to the invention for use in the treatment of diseases of the tooth root.
- the present invention also relates to a pharmaceutical composition of the invention for use in the treatment of animal or animal bites.
- the present invention also relates to a pharmaceutical composition of the invention for use in the treatment of inflammation.
- the present invention also relates to a pharmaceutical composition of the invention for use in the treatment of inflammation and viral, bacterial and / or mycotic diseases.
- the present invention also relates to a pharmaceutical composition according to the invention for the preparation of a medicinal preparation, in particular for the production of a medicinal preparation for the treatment of one of the diseases mentioned here.
- the present invention preferably relates to a pharmaceutical composition containing an unsaturated fatty acid or a derivative thereof, and a substance selected from the group consisting of glycerin, a glycerol derivative, tertiary butanol and mixtures thereof, wherein the unsaturated fatty acid or the derivative thereof with oxygen enriched.
- the present invention preferably relates to a pharmaceutical composition containing an unsaturated fatty acid or a derivative thereof, and a substance selected from the group consisting of glycerol, a glycerol derivative, tertiary butanol, DMSO and mixtures thereof, wherein the unsaturated fatty acid or the derivative thereof is oxygenated for use in the treatment of a disease of animals, especially of cloven-hoofed animals, in particular a disease of the hooves or udders.
- the plant protection agent according to the invention or the pharmaceutical composition according to the invention may contain an oxygen-enriched unsaturated fatty acid, in particular oleic acid A derivative of the unsaturated fatty acid and / or an oxygenated vegetable oil, for example olive oil, rapeseed oil, castor oil, sunflower seed oil, peanut oil, soybean oil, linseed oil, coconut oil, palm oil or tea tree oil, preferably olive oil.
- an oxygen-enriched unsaturated fatty acid in particular oleic acid A derivative of the unsaturated fatty acid and / or an oxygenated vegetable oil, for example olive oil, rapeseed oil, castor oil, sunflower seed oil, peanut oil, soybean oil, linseed oil, coconut oil, palm oil or tea tree oil, preferably olive oil.
- the pharmaceutical composition or the plant protection agent according to the invention preferably contains an unsaturated fatty acid or a derivative of the unsaturated fatty acid.
- Unsaturated fatty acids are predominantly and preferably even-numbered, straight-chain, aliphatic monocarboxylic acids having chain lengths of C 4 to C 2 4 and at least one double bond.
- the melting point of a fatty acid decreases with decreasing chain length and increasing number of double bonds.
- the at least one unsaturated fatty acid may in particular be an unsaturated fatty acid from a vegetable oil.
- the unsaturated fatty acid may be, for example, oleic acid, lauric acid, myristoleic acid, palmitoleic acid, icosenoic acid, cetoleic acid, erucic acid, calendic acid, linoleic acid, linolenic acid, ricinoleic acid or mixtures thereof.
- Particularly preferred is the unsaturated fatty acid oleic acid.
- the pharmaceutical composition or the plant protection agent according to the invention therefore preferably contains oleic acid, in particular oxygenated oleic acid.
- the at least one unsaturated fatty acid is preferably a vegetable fatty acid or is obtained from vegetable oil, for example from olive oil, rapeseed oil, castor oil, sunflower seed oil, peanut oil, soybean oil, linseed oil, coconut oil, palm oil or tea tree oil.
- the vegetable oil, the unsaturated fatty acid or the derivative of the unsaturated fatty acid, in particular the unsaturated fatty acid or the derivative of the unsaturated fatty acid is enriched with oxygen.
- the pharmaceutical composition or the plant protection agent according to the invention can also alternatively or additionally derivatives of at least one unsaturated fatty acid, especially the unsaturated fatty acids mentioned here.
- a derivative may be, for example, an ester of an unsaturated fatty acid.
- the ester is a methyl ester.
- the pharmaceutical composition or the plant protection agent according to the invention may also be free from derivatives of unsaturated fatty acids.
- the pharmaceutical composition or the plant protection agent according to the invention especially if they contain no glycerol, preferably contains no glycerol esters or contains at least glycerol esters only in small amounts or traces.
- the pharmaceutical composition or the plant protection agent according to the invention especially if they contain no glycerol, no triglycerides, digylcerides and / or monglycerides or contains at least triglycerides, digylcerides and / or monglycerides only in small amounts or traces.
- the pharmaceutical composition or the plant protection agent according to the invention preferably contains, especially if they contain no glycerol, in particular no oleic acid glycerol esters or contains at least oleic acid glycerol esters only in small proportions or traces.
- the pharmaceutical composition or the plant protection agent according to the invention preferably contains no oleic acid-containing triglycerides, digylcerides and / or monglycerides, in particular if they contain no glycerol, or contains at least triglycerides, digylcerides and / or monglycerides only in small amounts or traces.
- the pharmaceutical composition or the plant protection agent according to the invention preferably contains more pure unsaturated fatty acid and / or fatty acid methyl esters than fatty acid-containing glyceride esters.
- the pharmaceutical composition or the plant protection agent according to the invention contains glycerol
- the glycerol and the unsaturated fatty acid are preferably at least 50% by weight unesterified. Particularly preferably, only the proportion of the unsaturated fatty acid and the glycerol is esterified with each other, which leads to the esterification by the equilibrium reaction when mixing the unsaturated fatty acid with the glycerol.
- the pharmaceutical composition or the plant protection agent according to the invention preferably contains more pure oleic acid and / or oleic acid methyl ester than oleic acid-containing glyceride esters.
- the pharmaceutical composition or the plant protection agent according to the invention preferably contains at least one ozonized unsaturated fatty acid or at least one ozonated derivative of an unsaturated fatty acid Called ozonolysis, ozone is attached to CC double bonds to form ozonides
- the inventive pharmaceutical composition or the plant protection agent according to the invention preferably contains according to the invention ozonated oleic acid or at least one ozonated derivative of oleic acid.
- the pharmaceutical composition or the plant protection agent according to the invention preferably contains, as an intermediate, ozonides of the unsaturated fatty acid, in particular oleic acid, without being bound by theory.
- Ozonide refers to a class of chemical compounds that result from the addition of ozone to a double bond within an unsaturated chemical compound.
- Suitable methods for the ozonization of unsaturated fatty acids and vegetable oils are known.
- methods known, for example, for the ozonization of oils, for example for the production of Rizol can also be readily modified for the ozonization of unsaturated fatty acids.
- oxygen-enriched fatty acids and vegetable oils can be produced, for example, using conventional ozone generators.
- the unsaturated fatty acid or vegetable oil has an increased peroxide number after ozonization.
- the peroxide number is understood to mean the content of active oxygen which is bound in peroxidic form. Without being bound by theory, peroxides are basically secondary products of ozonides.
- the peroxide value of the oxygen-enriched fatty acid is preferably at least 50, in particular at least 100.
- the pharmaceutical composition or the plant protection agent according to the invention preferably contains glycerol and / or contains a glycerol derivative, preferably selected from the group consisting of 2,3-O-isopropylidene-glycerol, glycerol formal, glycerin carbonate and mixtures thereof.
- the pharmaceutical composition according to the invention or the plant protection agent according to the invention particularly preferably contains glycerol.
- the pharmaceutical composition or the plant protection agent according to the invention preferably contains glycerol, 2,3-O-isopropylidene-glycerol, glycerol formal and / or glycerol carbonate.
- the pharmaceutical composition or the plant protection agent according to the invention preferably contains glycerol, 2,3-O-isopropylidene-glycerol, glycerol formal or glycerol carbonate.
- the pharmaceutical composition or the plant protection agent according to the invention preferably contains 2,3-O-isopropylidene-glycerol.
- the pharmaceutical composition or the plant protection agent according to the invention preferably contains glycerol formal.
- the pharmaceutical composition or the plant protection agent according to the invention preferably contains glycerol carbonate.
- a pharmaceutical composition containing oxygen-enriched oleic acid and glycerol.
- a plant protection agent containing oxygen-enriched oleic acid and glycerol is particularly preferred.
- Glycerol differs from the DMSO used in WO 2013/1531 1 1 AI not only by the fact that glycerol is safer for the health, but also in that DMSO penetrates easily as a penetration enhancer into the skin while an active ingredient with transported into the body while glycerol at least not as strong and fast as DMSO penetrates the skin.
- DMSO a mixture of the oxygen-enriched fatty acid with glycerol in a topical application to a different action attack as in a mixture with DMSO. It was surprisingly found that infections and / or inflammations with a mi be treated with glycerol or a Glycerinderivat despite the different effect attack at least as well.
- a mixture of oxygen-enriched unsaturated fatty acid and glycerol or a glycerol derivative has a favorable consistency, which can be incorporated well into desired products, for example medical preparations.
- such a mixture can be stored well and for a long time.
- the consistency can be low-viscosity, in particular less viscous than ozonated vegetable oils from the prior art.
- the pharmaceutical composition according to the invention or the plant protection agent according to the invention contains tertiary butanol.
- the ozonized unsaturated fatty acid can be mixed in particularly well.
- the oxygen-enriched unsaturated fatty acid or a derivative of this or an oxygen-enriched oil can be mixed particularly well and in comparatively high dosages with tertiary butanol.
- a mixture of oxygen-enriched unsaturated fatty acid and tertiary butanol has an advantageous consistency, which can be incorporated well into desired products, for example medical preparations.
- such a mixture can be stored well and for a long time.
- the consistency can be low-viscosity, in particular less viscous than ozonated vegetable oils from the prior art.
- the pharmaceutical composition or the plant protection agent according to the invention contains the oxygen-enriched unsaturated fatty acid or the derivative of this or the vegetable oil in an amount of at least 0.5% by weight. In a preferred embodiment, the pharmaceutical composition or the plant protection agent according to the invention contains the oxygen-enriched unsaturated fatty acid or the derivative of this or the vegetable oil in an amount of at least 0.5% by volume.
- the pharmaceutical composition or the plant protection agent according to the invention contains the oxygen-enriched unsaturated fatty acid or the derivative of this or the vegetable oil in an amount of at least 1% by weight.
- the pharmaceutical composition or the plant protection agent according to the invention contains the oxygen-enriched unsaturated fatty acid or the derivative of this or the vegetable oil in an amount of at least 1% by volume.
- the pharmaceutical composition or the plant protection agent according to the invention contains the oxygen-enriched unsaturated fatty acid or the derivative of this or the vegetable oil in a proportion of at most 7.5% by volume. In a preferred embodiment, the pharmaceutical composition or the plant protection agent according to the invention contains the oxygen-enriched unsaturated fatty acid or the derivative of this or the vegetable oil in a proportion of at most 7.5% by weight. In a preferred embodiment, the pharmaceutical composition or the plant protection agent according to the invention contains the oxygen-enriched unsaturated fatty acid or the derivative of this or the vegetable oil in an amount of at most 25% by volume when dissolved in tertiary butanol.
- the pharmaceutical composition or the plant protection agent according to the invention contains the oxygen-enriched unsaturated fatty acid or the derivative of this or the vegetable oil in a proportion of at most 25 wt .-% when it is dissolved in tertiary butanol.
- the pharmaceutical composition or the plant protection agent according to the invention contains the oxygen-enriched unsaturated fatty acid and the glycerol or glycerol derivative in a volume ratio of 1 to 20 to 20 to 1.
- the pharmaceutical composition or the plant protection agent according to the invention contains those with oxygen enriched unsaturated fatty acid and the glycerol or glycerol derivative in a volume ratio of 1 to 15 to 15 to 1.
- the composition or the plant protection agent according to the invention contains the oxygen-enriched unsaturated fatty acid and the glycerol or glycerol derivative in a volume ratio of 1 to 1 1 to 1: 1 to 1.
- the composition or the plant protection agent according to the invention contains the oxygen-enriched unsaturated fatty acid Re and the glycerol or glycerol derivative in a volume ratio of 1 to 2 to 2 to 1.
- the pharmaceutical composition or the plant protection agent according to the invention contains the oxygen-enriched unsaturated fatty acid and the glycerol or glycerol derivative in a volume ratio of 1 to 50 to 1 to 10.
- the pharmaceutical composition or the inventive plant protection product contains the oxygen-enriched unsaturated fatty acid and the glycerin or glycerin derivative in a volume ratio of 1 to 25 to 1 to 15.
- the pharmaceutical composition or the plant protection agent according to the invention contains the oxygen-enriched unsaturated fatty acid and the tertiary butanol in a volume ratio of 1 to 50 to 1 to 3.
- the pharmaceutical composition or the plant protection agent according to the invention contains Oxygen-enriched unsaturated fatty acid and the tertiary butanol in a volume ratio of 1 to 20 to 1 to 4.
- the pharmaceutical composition or the plant protection agent according to the invention contains the oxygen-enriched unsaturated fatty acid and the tertiary butanol in a volume ratio of 1 to 15 bis 1 to 5.
- a preferred embodiment of a pharmaceutical composition or the plant protection agent according to the invention contains at least 1 g of the oxygen-enriched unsaturated fatty acid, in particular oleic acid, or of the vegetable oil per 10 ml of glycerol or glycerol derivative.
- a preferred embodiment of a pharmaceutical composition or of the plant protection agent according to the invention contains at least 1 g and at most 20 g of the oxygen-enriched unsaturated fatty acid, in particular oleic acid, or the vegetable oil per 10 ml of glycerol or glycerol derivative.
- a particularly preferred embodiment of a pharmaceutical composition or of the plant protection agent according to the invention contains 10 g of the oxygen-enriched unsaturated fatty acid, in particular oleic acid, or of the vegetable oil per 10 ml of glycerol or glycerol derivative.
- a preferred embodiment of a pharmaceutical composition or of the plant protection agent according to the invention comprises at least 1 g of the oxygen-enriched unsaturated fatty acid, in particular oleic acid, or of the vegetable oil per 10 ml of tertiary butanol.
- a favorite zugte embodiment of a pharmaceutical composition or the plant protection agent according to the invention contains at most 2 g of the oxygen-enriched unsaturated fatty acid, in particular oleic acid, or the vegetable oil to 5 ml of tertiary butanol.
- a preferred embodiment of a pharmaceutical composition or the plant protection agent according to the invention contains about 1 g of the oxygen-enriched unsaturated fatty acid, in particular oleic acid, or the vegetable oil to 5 ml of tertiary butanol.
- the pharmaceutical composition or the crop protection agent according to the invention additionally contains at least one siderophore.
- Siderophores are a group of about 200 iron-binding small molecules and oligopeptides, which are formed by aerobic bacteria, fungi and plant roots and secreted into the surrounding medium.
- the at least one siderophore may, for example, be selected from the group consisting of enterobactins, ferrioxamines, pyoverdines, mycobactins, exochelines, ferrichromes, citrate-containing siderophores and mixtures thereof.
- the siderophore may be of bacterial or fungal origin, for example.
- the pharmaceutical composition or the plant protection agent according to the invention contains no dimethyl sulfone (methylsulfonylmethane, MSM), that is to say it is free from dimethylsulfone.
- the pharmaceutical composition or the plant protection agent according to the invention is in microencapsulated form.
- the pharmaceutical composition or the plant protection agent according to the invention are present as microcapsules.
- the pharmaceutical composition according to the invention is in microencapsulated form.
- the crop protection agent according to the invention is in microencapsulated form.
- Microencapsulation is a technique by which solid, liquid or gaseous substances, in the present invention thus the oxygen-enriched unsaturated fatty acid or the derivative of this or the oxygen-enriched oil, are surrounded in minute portions with a shell and thus immobilized become. Microencapsulation is thus a form of inclusion immobilization.
- the term microencapsulation is understood to mean embedding at least at least one component (active ingredient component) with the aid of at least one second component (sheath component).
- the following two types of microencapsulation are possible: a) Matrix encapsulation:
- the or the at least one active ingredient component is homogeneously mixed with the cladding component and a particle is formed in which the active substance component is uniformly distributed.
- the release will determine either the diffusion of the drug component into the environment or the rate of degradation of the matrix release;
- Core-shell encapsulation The drug component is enveloped with an envelope component. It creates a real capsule with one or more cases, eg. B. a polymer.
- the hull fracture usually produces a complete release of the active ingredient component in a short time ("burst"). But it is also possible to produce an extremely slow release by the appropriate choice of the shell.
- the active ingredient component in the case of microencapsulation is preferably the pharmaceutical compositions or the plant protection agent according to the invention, in particular the oxygen-enriched unsaturated fatty acid or the derivative thereof or the oil enriched with oxygen.
- any further substances such as, for example, glycerol, a glycerol derivative, tertiary butanol, DMSO, siderophores or polyvinylpyrrolidone may belong to the active component of the microcapsule.
- the sheath component is preferably gelatin or a biodegradable polyester compound, in particular polylactic acid, copolymers of lactic-glycolic acid (PLGA), star-branched polymers in which PLGA chains are bonded to a central glucose molecule, or polyhydroxy butter
- the shell component is gelatin or a biodegradable polyhydroxyalkanoate
- the shell component is a biodegradable polyester compound
- the shell component is gelatin.
- the microencapsulation may be a matrix encapsulation or a core-shell encapsulation.
- the microencapsulation is preferably a matrix encapsulation.
- the microencapsulation advantageously offers the possibility of well bonding the pharmaceutical compositions according to the invention or the plant protection agent according to the invention and their oxygen-enriched substances and releasing them over a certain period of time or releasing them over a certain period of time.
- the oxygenated unsaturated fatty acid or derivative thereof or the oxygenated oil may be delivered evenly and slowly over a long period of time, which is advantageous in both pharmaceutical application and pesticide application.
- the oxygenated unsaturated fatty acid or the derivative thereof or the oxygenated oil may be orally taken as microcapsules, the release being made only at a desired location, for example, in the intestine. This may also be beneficial for systemic treatment of diseases in animals, particularly the corresponding uses described below for the treatment of diseases of the claws and udders, for example because the microcapsules may be readily administered with the feed.
- the pharmaceutical composition or the pesticide comprises liposomes.
- the pharmaceutical composition or the plant protection agent ie in particular the unsaturated fatty acid, the derivative of this or the vegetable oil and the additives such as glycerol or a glycerol derivative of liposomes are enclosed.
- the pharmaceutical composition or the pesticide is contained in liposomes.
- Liposomes are vesicles that include aqueous phases and whose membrane shell consists of a double layer of molecules that have both a non-polar and a polar part, and are therefore called amphiphilic. Most of the membrane-forming molecules are substances from the class of lipids, such as phospholipids and fatty acids.
- the liposomes advantageously enable the pharmaceutical composition or the plant protection agent to be brought to the site of action in a protected manner.
- the term liposomes also means lipoid particles, ie lipid particles, in particular solid lipid particles, preferably lipid nanoparticles.
- the pharmaceutical composition or the pesticide is also contained in lipoid particles.
- niosomes or polymeromas can also be used.
- the invention thus also relates to a pharmaceutical composition or a plant protection agent containing a vegetable oil or an unsaturated fatty acid or a derivative of the unsaturated fatty acid, wherein the vegetable oil or the unsaturated fatty acid or the derivative of the unsaturated fatty acid is oxygenated, in particular ozonated, and wherein the Vegetable oil or the unsaturated fatty acid or the derivative of the unsaturated fatty acid in liposomes or in niosomes or in polymeromas, preferably in liposomes.
- the invention thus relates in particular to a pharmaceutical composition or a crop protection agent containing an ozonated oleic acid packed in liposomes.
- liposomes in combination with the pharmaceutical composition or the plant protection agent according to the invention has the technical advantage that the active substances can be released in a controlled manner over a relatively long period of time and are protected by the liposomes.
- selective transport of the active substances is also possible for the use of liposomes.
- the liposomes are readily biodegradable and environmentally compatible.
- a particularly preferred composition of a pharmaceutical composition or of a plant protection agent according to the invention is, for example, an ozonized fatty acid, in particular oleic acid, and a phospholipid, in particular a strongly phosphatidylcholine containing phospholipid, for example, the phospholipid containing 60% to 80% phosphatidylcholine as the soy phospholipid LIPOID S 75 ® the company Lipoid, Ludwigshafen, Germany.
- the ratio of ozonized fatty acid to phospholipid is about 3 to 1 to 1 to 2, more preferably about 2 to 1.
- the composition is dissolved in a solvent, for example, phosphate buffered saline (PBS) and then dried with an ethanolic solution.
- PBS phosphate buffered saline
- the composition thus obtained is a preformulation which advantageously forms liposomes on contact with moisture and / or with organic tissue.
- An alternative composition of a pharmaceutical composition according to the invention or a plant protection agent according to the invention on the basis of liposomes can be, in addition to the oxygenated vegetable oil or oxygen-enriched unsaturated fatty acid or the oxygen-enriched unsaturated fatty acid derivative, a phospholipid, in particular a phospholipid containing strong phosphatidylcholine, for example around 60%) to 80% o phosphatidyl choline-containing phospholipids such as soya phospholipid LIPOID S contained 75 ® Lipoid, Ludwigshafen, Germany, and a solvent such as PBS or NAT riumcitrat.
- a phospholipid in particular a phospholipid containing strong phosphatidylcholine, for example around 60%
- 80% o phosphatidyl choline-containing phospholipids such as soya phospholipid LIPOID S contained 75 ® Lipoid, Ludwigshafen, Germany
- a solvent such as PBS or NAT riumcitrat.
- the present invention solves the underlying technical problem also by providing products, in particular medical preparations and products containing or having a pharmaceutical composition according to the invention.
- Such products may be, for example, vaginal suppositories, medical wound coverings or patches, pastes, ointments, rinses, solutions, gels, lacquers, deodorants, soaps, creams, lotions, shampoos, diapers or panty liners.
- the present invention also solves the underlying technical problem by providing vaginal suppositories containing a pharmaceutical composition according to the invention.
- the vaginal suppositories according to the invention are particularly suitable for the prevention and treatment of diseases of the genitourinary tract and / or the anal region, for example by pathogens frequently occurring there, such as chlamydia, streptococci and / or fungi.
- the vaginal suppositories according to the invention are characterized in particular by the fact that both bacterial as well as simultaneous or often subsequent fungal infections of the urogenital area can be treated.
- Diapers or panty liners according to the invention which contain a pharmaceutical composition according to the invention are suitable for the prevention of such diseases.
- diapers and panty liners can be prevented to migrate pathogens, such as streptococcus into the urogenital tract.
- the diapers are preferably disposable diapers.
- These diapers which are known per se in their construction, preferably consist of a absorbent core enriched in a superabsorber and surrounded by a (non-woven) plastic material.
- plastic here can be called polyester. So that the penetrating liquid can be kept inside, a diaper is surrounded by a plastic film.
- the skin pad is broadly considered to be the area in which the diaper rests against the genital area.
- the pharmaceutical composition of the invention may be applied at least partially thin.
- the cover layer is the outwardly facing diaper surface which has adhesive strips for fixing the diaper.
- infant care as in incontinence here in particular, but not exclusively in Care of the elderly should be prevented by the coating by the pharmaceutical composition according to the invention in the genital area of diaper dermatitis or other infections or these should be effectively combated if they are already present.
- the same observations apply as described for the panty liners.
- the combined anti-inflammatory, antibacterial, antiviral and / or antifungal activity of the respective effective ozonized agent can be utilized according to individual requirements.
- the present invention solves the underlying technical problem also by providing a Unterlegvlieses, which is at least partially coated with a pharmaceutical composition according to the invention.
- a Unterlegvlieses which is at least partially coated with a pharmaceutical composition according to the invention.
- absorbent nonwoven pads were used, which are provided on their one, in the application of the respective skin side facing with a thin coating of a pharmaceutical composition according to the invention. These pads can laterally have an opening for quick and easy change in eg a lying catheter.
- an effective germicidal agent is available which protects the affected areas against further infection.
- the present invention solves the underlying technical problem also by providing a catheter which is at least partially coated with a pharmaceutical composition according to the invention.
- the pharmaceutical composition according to the invention is preferably mixed with methyl cellulose as carrier.
- the present invention also solves the underlying technical problem by providing medical wound dressings or patches containing a pharmaceutical composition of the invention.
- the medical wound coverings and patches according to the invention are particularly suitable for the treatment of wound diseases of the skin.
- Areas of application are, for example, acne plasters, herpes plasters, wound healing plasters for the treatment of "ulcus cruris”, wound healing plasters for the treatment of "diabetic foot”, covers for the treatment of inflammations of the nail bed or covers for the treatment of foot and nail fungus diseases.
- the pharmaceutical composition may additionally contain sandalwood or an artificial or natural sandalwood preparation, in particular Sandalor (Sandal Pentanol, 3-methyl-5- (2,2,3-trimethyl-3-cyclopenten-1-yl) -2-pentanol).
- sandalwood preparations can advantageously assist wound healing positively by keratinocyte stimulation.
- the invention also relates to a tick plaster or a wart patch with a pharmaceutical composition according to the invention as an active ingredient.
- a medical skin cover which can serve to treat infections of the skin, with a skin layer and a cover layer, wherein the skin layer is provided with an anti-inflammatory and / or antibacterial and / or antiviral and / or antifungal agent, the a pharmaceutical composition according to the invention includes.
- the covering layer may have at least partially an adhesive layer on the side facing or facing away from the skin.
- the said agent comprising the pharmaceutical composition according to the invention can be applied to the skin pad or the skin pad is impregnated with the agent.
- a pharmaceutical composition according to the invention has the advantage of acting in many ways. Basically, it is attributed to anti-inflammatory as well as antibacterial, antiviral and antifungal activity at the same time. But it is likely in the application that depending on the application only a part of the possible spectrum of action is needed. For antibacterial and antifungal efficacy, for example, in athlete's foot can be used at the same time, while only a bacterial inflammation, such as the so-called grind in children, various types of acne or other skin inflammation will be used antibacterial efficacy.
- the skin layer can be fixed in a simple manner at the point where the pharmaceutical composition according to the invention is intended to act.
- the skin layer is attached to the adhesive layer.
- the adhesive layer is then preferably over the entire surface mounted on the cover layer.
- the covering layer has a larger area than the skin layer. In this way, it towers over the skin surface and not only serves to fix it, but also to fix the skin cover on the skin as a whole.
- the inventive, medical skin cover is designed in the form of a plaster.
- the medical skin cover formed in such a way or in another way can be cut to size, so that it is available by the meter and a strip of it can be cut off as required.
- the skin cover may be provided with a skin pad which is in various embodiments of different length and / or width. In this way, the skin cover can be adapted to the application.
- the treatment of an inflamed pimple or boil will require a different sizing of the skin patch than grind or athlete's foot.
- the present invention solves the underlying technical problem also by providing pastes, ointments, rinses or solutions containing a pharmaceutical composition according to the invention. Due to the advantageous consistency of the pharmaceutical composition according to the invention, it can be introduced and used particularly well in pastes, ointments, rinses or solutions, for example as a medicinal preparation.
- the present invention also solves the technical problem on which it is based by providing deodorants, soaps, creams, lotions or shampoos containing a pharmaceutical composition according to the invention. Due to the advantageous consistency of the pharmaceutical composition according to the invention, these can be incorporated particularly well in deodorants, soaps, creams, lotions or shampoos. Thus, the pharmaceutical composition according to the invention can be used, for example, for the prophylaxis before or for the treatment of diseases of the skin.
- the present invention solves the underlying technical problem also by a medical preparation in which a pharmaceutical composition according to the invention is applied to a carrier material on a vegetable and / or plastic basis, and that with a polymeric coating or a coating of a natural or synthetic Wax is provided, wherein the carrier material and the coating are substantially biodegradable.
- a medical preparation in which a pharmaceutical composition according to the invention is applied to a carrier material on a vegetable and / or plastic basis, and that with a polymeric coating or a coating of a natural or synthetic Wax is provided, wherein the carrier material and the coating are substantially biodegradable.
- PHB polyhydroxybutyrate
- the present invention solves the underlying technical problem also by providing gels or paints containing a pharmaceutical composition according to the invention.
- gels or lacquers can be applied well to teeth or in the tooth area, either directly or through wound dressings or patches.
- the present invention also solves the underlying technical problem by providing a medical preparation containing a pharmaceutical composition of the invention and having mucoadhesive properties.
- the medical preparation advice to contain or be formed from edible paper.
- Such medical preparations are suitable, for example, for the treatment of wound diseases in the mouth, for example for the treatment of aphthae.
- the invention also relates to a medical preparation for treating the tooth root, in particular gangrene, which is used in the form of paper tips which at least partially have a coating with a pharmaceutical composition according to the invention.
- the paper tips are length-calibrated. This allows precise placement of the paper tips by means of the endometry method.
- the invention further relates to the use of the medical preparation according to the invention, in particular of the paper tips according to the invention as a temporary insert into the endodont.
- the present invention relates to a composition according to the invention and products containing the same, except for their use in the oral and dental field.
- the present invention relates to a pharmaceutical composition according to the invention and products containing the same, except paper tips containing a pharmaceutical composition and in particular their use as a temporary insert into the endodont.
- the present invention solves the underlying technical problem also by providing a medical preparation in which a pharmaceutical composition according to the invention is applied to a carrier material, wherein the carrier material is a sponge or a hydrogel.
- a medical preparation is well-suited for treating infections of the ears and / or the ear canal.
- the present invention also solves the technical problem on which it is based by capsules containing a pharmaceutical composition according to the invention.
- capsules may preferably be designed such that they first dissolve in the intestine, in particular small intestine, so that the pharmaceutical composition according to the invention is released there and can act.
- capsules are preferred which, when taken orally, first dissolve in the intestine, in particular the small intestine, and release the pharmaceutical composition according to the invention.
- Such capsules are used to treat intestinal diseases.
- Such capsules preferably serve to treat bowel diseases caused by clostridia, for example by Clostridium difficile.
- the pharmaceutical composition according to the invention can be present in microcapsules or liposomes, which are then released through the capsules in the gastrointestinal tract.
- the present invention thus also relates to the pharmaceutical composition according to the invention for use in the gastrointestinal tract.
- polyhydroxybutyrate PHB
- PHB polyhydroxybutyrate
- the present invention also relates to a pharmaceutical composition according to the invention, for example in the form of an ointment, a cream, a paste, a solution, for use in the topical treatment of mild to moderate inflammations in the ileocecal region, e.g. Crohn's disease.
- the hitherto conventional steroids or preparations such as sulfasalazine / mesalazine can advantageously be saved or replaced.
- the present invention also relates to a nasal spray, nasal ointment or a nasal rinsing solution containing at least one unsaturated fatty acid or a derivative thereof or a vegetable oil, wherein the at least one unsaturated fatty acid or the derivative thereof or the vegetable oil is oxygenated.
- the nasal spray, the nasal ointment or the nasal rinse solution additionally contains glycerol, paraffinum subliquidum and / or myrsitic acid propyl ester.
- the nasal spray, the nasal ointment or the nasal rinse solution additionally contains glycerol.
- the nasal spray, the nasal ointment or the nasal rinse solution additionally contains paraffinum subliquidum.
- the nasal spray, the nasal ointment or the nasal rinse solution additionally contains propyl myristate.
- a pharmaceutical composition according to the invention may also be used on a solid support, for example small tubes of absorbent pulp or cellulose materials, PHB, or PU foams containing the pharmaceutical composition, for example in the form of an ointment Keep in place in the nasal entry area.
- the present invention also relates to a pharmaceutical composition according to the invention for use in the treatment of sinusitis, but also for the treatment of runny nose, hay fever and other nasal infections, for example infection by MRSA bacteria in the nasal area.
- the present invention also relates to a skin bleaching agent comprising a pharmaceutical composition according to the invention.
- the present invention also relates to a pharmaceutical composition according to the invention for use as a skin bleaching agent, for example for the treatment of age spots.
- the present invention solves the underlying technical problem also by using a pharmaceutical composition according to the invention for the preparation of a medicinal preparation.
- compositions according to the invention are suitable for the treatment of viral, bacterial and / or mycotic diseases.
- the previous application on appropriate carrier media increases the duration of action and the effect of effect considerably.
- suitable carrier media can readily select suitable carrier media.
- the present invention also relates to a pharmaceutical composition according to the invention for the treatment of viral, bacterial and / or mycotic diseases or the use of a pharmaceutical composition according to the invention for the treatment of viral, bacterial and / or mycotic diseases.
- the invention also relates to Use of a pharmaceutical composition according to the invention for the preparation of a medicinal preparation for the treatment of a disease or infection mentioned here.
- This may in particular be a disease caused by anaerobic bacteria.
- the pharmaceutical composition according to the invention is preferably used bactericidally.
- the pharmaceutical composition according to the invention is used fungicidally.
- the pharmaceutical composition according to the invention is used antivirally. But it can also be provided a bacteriostatic or fungistatic application.
- a pharmaceutical composition of the invention may be used to treat disease by Borrelia sp., Enterococcus sp., Streptococcus sp., Staphylococcus sp., Propionibacterium sp., Chlamydia sp., Trichophyton sp., Candida sp., Microsporum sp., Herpes simplex - Viruses and / or TBE viruses are used.
- Infections may be treated by Staphylococcus aureus, Staphylococcus albus, Staphylococcus hemolyticus or Enterococcus faecalis.
- the treatment of infections by Trichophyton xnentagrophytes, Trichophyton purpureum, Microsporon audouini or Microsporon lensonum is also possible.
- the treatment of acne caused by Propionibacterium acnes is possible.
- a pharmaceutical composition according to the invention for the treatment of disease by clostridia, so Clostridium sp. Be used.
- a pharmaceutical composition of the invention is preferably used for the treatment of disease by Clostridium difficile, in particular in the gastrointestinal tract, preferably in the intestine, particularly preferably in the small intestine. Preference is given to the use in a capsule.
- sp the abbreviation "sp.””Species” is thus understood to mean the corresponding taxonomic species.
- “Borrelia sp” is understood to mean all Borrelia, which are grouped under the species “Borellia”.
- a pharmaceutical composition according to the invention can be used for the treatment of diseases of the genitourinary tract and / or the anal region.
- the pharmaceutical composition according to the invention is characterized in particular by the fact that, on the one hand, difficult-to-treat bacterial diseases can be treated, for example by chlamydiae, in particular without the administration of antibiotics, and, on the other hand, additional fungal infections can be avoided.
- a pharmaceutical composition according to the invention can also be used for the treatment of diseases of the tooth root.
- a pharmaceutical composition according to the invention can also be used for the treatment of animal bites or animal bites. Preference is given to the treatment of tick bites, for example by "tick plasters.”
- the inventive pharmaceutical composition can treat both Borrelia sp., Borrelia burgdorferi, and FMSE virus infections.
- a pharmaceutical composition according to the invention for example in the form of ointments, solutions, tinctures but also patches and pads can also be used for the treatment of warts. It has surprisingly been found that the pharmaceutical composition according to the invention also has anti-inflammatory properties.
- a pharmaceutical composition according to the invention can also be used for the treatment of inflammations.
- a pharmaceutical composition according to the invention can also be used for the treatment of inflammation and simultaneous treatment of viral, bacterial and / or mycotic diseases mentioned here. Thus, preference is given to an antimicrobial and at the same time anti-inflammatory treatment.
- a use of a pharmaceutical composition according to the invention is a use of a pharmaceutical composition according to the invention as a first or second medical indication.
- a pharmaceutical composition according to the invention in particular as a first or second medical indication, in the form of the products described herein, for example in the form of medical wound dressings, patches, pastes, ointments, rinses, solutions, gels, varnishes, deodorants, soaps, creams, Lotions, shampoos, diapers, panty liners, medicated preparations or capsules.
- the present invention solves the underlying technical problem also by methods in which diseases, in particular diseases described here, are treated with the pharmaceutical composition according to the invention.
- the present invention also relates to a crop protection agent comprising a vegetable oil, an unsaturated fatty acid or a derivative of an unsaturated fatty acid, wherein the vegetable oil, the unsaturated fatty acid or the derivative of the unsaturated fatty acid is oxygenated, in particular ozonated.
- the invention thus also relates to the use of vegetable oils, unsaturated fatty acids and derivatives of unsaturated fatty acids enriched in oxygen, in particular ozonated, as crop protection agents.
- the pesticide is preferably a bactericide and / or virucide and / or fungicide.
- the pesticide is preferably a bactericide, virucide or fungicide.
- oxygen-enriched vegetable oils and especially unsaturated fatty acids are not only suitable as pharmaceutical agents for the treatment of human diseases, but also for the treatment of diseases, in particular bacterial, viral or fungal diseases of plants.
- the crop protection agents according to the invention are environmentally friendly and biodegradable. They can also be applied simply in the form of sprays or solutions to the plants or to certain plant parts, for example by spraying them on.
- the present invention thus also relates to the use of a vegetable oil or an unsaturated fatty acid or a derivative of an unsaturated fatty acid, wherein the vegetable oil, the unsaturated fatty acid or the derivative of the unsaturated fatty acid are oxygenated as pesticides and for the treatment of diseased plants, in particular infected with bacteria, viruses or fungi.
- the invention thus also relates to a method for treating Treatment of such diseased plants, in which a vegetable oil or an unsaturated fatty acid or a derivative of an unsaturated fatty acid is applied to the plant parts, wherein the vegetable oil, the unsaturated fatty acid or the derivative of the unsaturated fatty acid are enriched with oxygen.
- the crop protection agent additionally contains a filler.
- the crop protection agent additionally contains a substance selected from the group consisting of glycerol, a glycerol derivative, DMSO, oil, fat, paraffin, methanol, ethanol, butanol, in particular tertiary butanol, fat, or polyvinylpyrrolidone (PVP).
- the crop protection agent contains polyvinylpyrrolidone.
- the present invention preferably also relates to a plant protection agent according to the invention, wherein the oxygen-enriched unsaturated fatty acid or the derivative of this or the vegetable oil is an ozonide and the crop protection agent additionally contains a substance selected from the group consisting of glycerol, a glycerol derivative, DMSO, tertiary butanol , Polyvi- nylpyrro lidon and mixtures thereof.
- the crop protection agent contains glycerol or a glycerol derivative. Specific embodiments thereof are described above.
- the plant protection product contains paraffin.
- the plant protection product contains no DMSO as solvent, in particular DMSO at most in traces, more preferably no DMSO.
- the pesticide preferably additionally contains a surfactant.
- the present invention alternatively also relates to a plant protection agent according to the invention, wherein the oxygen-enriched unsaturated fatty acid or the derivative thereof or the vegetable oil is an ozonide and the pesticide additionally contains a surfactant.
- surfactants suitable for crop protection agents are known to the person skilled in the art, for example Tween.
- Oils, for example rapeseed oils, are used as natural pesticides against aphids.
- aphids typically excrete large amounts of protein sugar-deficient, sugar-containing solution, the so-called honeydew. This often serves as a nutrient medium for fungi such as black and black throats, so that an aphid infestation is often associated with a fungal attack.
- the crop protection agent contains at least 0.5 percent by weight of the oxygenated vegetable oil or the oxygenated unsaturated fatty acid or the oxygenated derivative of the unsaturated fatty acid. More preferably, the crop protection agent contains at least 1% by weight of the oxygenated vegetable oil or the oxygenated unsaturated fatty acid or the oxygenated derivative of the unsaturated fatty acid. In a preferred embodiment, the crop protection agent contains at most 7.5% by weight of the oxygenated vegetable oil or the oxygenated unsaturated fatty acid or the oxygenated derivative of the unsaturated fatty acid.
- the crop protection agent contains at least 0.5% by volume of the oxygenated vegetable oil or the oxygenated unsaturated fatty acid or the oxygenated derivative of the unsaturated fatty acid. More preferably, the crop protection agent contains at least 1 volume percent of the oxygenated vegetable oil or the oxygenated unsaturated fatty acid or the oxygenated derivative of the unsaturated fatty acid. In a preferred embodiment, the crop protection agent contains at most 20% by volume of the oxygenated vegetable oil or the oxygenated unsaturated fatty acid or the oxygenated derivative of the unsaturated fatty acid. In a preferred embodiment, the crop protection agent contains at most 7.5% by volume of the oxygenated vegetable oil or the oxygenated unsaturated fatty acid or the oxygenated derivative of the unsaturated fatty acid.
- the crop protection agent is in microencapsulated form. Preferred embodiments of such crop protection agents and alternatives are further described above.
- the combination of the plant protection agents according to the invention with microcapsules has the technical advantage that the plant protection product can be controlled, for example after spraying onto the plants, and delivered over a longer period of time.
- the microcapsules are well degradable as packaging material of the plant protection product and environmentally friendly.
- the crop protection agent has liposomes. Preferred embodiments of such crop protection agents and alternatives are described further above.
- the combination of the plant protection agents according to the invention with liposomes has the technical advantage that the plant protection product can be controlled, for example after spraying onto the plants, and delivered over a longer period of time.
- the liposomes are well degradable as packaging material of the plant protection product and environmentally friendly.
- a particularly preferred composition of a plant protection agent for example, an ozonated fatty acid, especially oleic acid, and a phospholipid, in particular a strong phosphatidylcholine-containing phospholipid, for example, about 60% to 80% phosphatidyl choline-containing phospholipids such as soya phospholipid LIPOID S 75 ® Lipoid, Ludwigshafen, Germany.
- the ratio of ozonized fatty acid to phospholipid is about 3 to 1 to 1 to 2, more preferably about 2 to 1.
- the composition is dissolved in a solvent, for example, phosphate buffered saline (PBS) and then dried with an ethanolic solution.
- PBS phosphate buffered saline
- the composition thus obtained is a preformulation which advantageously forms liposomes on contact with moisture and / or with organic tissue. It comes in an advantageous manner to a slow and spontaneous liposome formation, which can be used for a sustained release in the treatment of plants.
- composition of a liposome-based crop protection agent may additionally comprise, in addition to the oxygenated vegetable oil or the oxygen-enriched unsaturated fatty acid or the oxygen-enriched derivative of the unsaturated fatty acid Phospholipid, in particular a phosphatidylcholine-containing phospholipid, for example, containing the 60% to 80% phosphatidylcholine phospholipid such as the soy phospholipid LIPOID S 75 ® the company Lipoid, Ludwigshafen, Germany and sodium citrate.
- a phosphatidylcholine-containing phospholipid for example, containing the 60% to 80% phosphatidylcholine phospholipid such as the soy phospholipid LIPOID S 75 ® the company Lipoid, Ludwigshafen, Germany and sodium citrate.
- Preferred is a crop protection agent containing an unsaturated fatty acid or a derivative thereof, wherein the unsaturated fatty acid is oxygen-enriched, and an organic solvent for the unsaturated fatty acid.
- the crop protection agent preferably contains, in addition to the at least one oxygen-enriched unsaturated fatty acid, in particular oleic acid, or the at least one oxygen-enriched derivative thereof also a solvent suitable for the unsaturated fatty acid or for the derivative.
- the solvent may be, for example, glycerol, a glycerol derivative, butanol, in particular tertiary butanol, methanol and / or dimethyl sulfoxide (DMSO).
- DMSO dimethyl sulfoxide
- the solvent is glycerol or DMSO.
- An ethanolic solution can also be used.
- a plant protection agent containing oxygen-enriched oleic acid and glycerol, a glycerol derivative or DMSO is particularly preferred.
- a mixture of oxygen-enriched unsaturated fatty acid and glycerol, a glycerol derivative or DMSO has an advantageous consistency, which can be incorporated well into desired products, in particular a crop protection agent.
- a mixture can be stored well and for a long time.
- the crop protection agent contains the oxygen-enriched unsaturated fatty acid and the organic solvent in a volume ratio of 1 to 20 to 20 to 1.
- the crop protection agent contains the oxygen-enriched unsaturated fatty acid and the organic solvent in a volume ratio of 1 to 15 to 15 to 1.
- the plant protection agent contains the oxygen-enriched unsaturated fatty acid and the organic solvent in a volume ratio of 1 to 11 to 11 to 1.
- the plant protection product contains Oxygen-enriched unsaturated fatty acid and the organic solvent in a volume ratio of 1 to 2 to 2 to 1.
- a preferred embodiment of the plant protection agent contains at least 1 g and at most 20 g of the oxygen-enriched unsaturated fatty acid, in particular oleic acid, to 10 ml of DMSO.
- a particularly preferred embodiment of the crop protection agent contains 10 g of the oxygen-enriched unsaturated fatty acid, in particular oleic acid, to 10 ml of DMSO.
- the crop protection agent according to the invention is used to combat Oomycetes.
- the invention therefore also relates to the use of a crop protection agent according to the invention for controlling Oomycetes on plants.
- the invention therefore also relates to the use of a crop protection agent according to the invention for controlling the late blight of late blight or the control of downy mildew.
- the present invention also relates to a pharmaceutical composition containing an oxygenated vegetable oil and / or an oxygenated fatty acid and / or an oxygenated derivative of the fatty acid and a medical preparation containing such a pharmaceutical composition, wherein the pharmaceutical composition or medical A preparation for use in the treatment of diseases in animals, in particular mammals serve.
- the pharmaceutical composition or medical A preparation for use in the treatment of diseases in animals, in particular mammals serve.
- Preference is given to the use for the treatment of lehufigen animals, especially cattle, pigs, camels, goats, sheep, deer, giraffe hippos and / or antelopes.
- Particularly preferred is the treatment of lehufigen farm animals, especially cattle or sheep.
- Particularly preferred is the treatment of diseases of claws and / or udders, especially of claws.
- a pharmaceutical composition according to the invention for the treatment of animals contains no DMSO as solvent, in particular DMSO at most in traces, particularly preferably no DMSO.
- Particularly preferred is the treatment of bacterial diseases of the claws and / or the udder. Particularly preferred is the treatment of inflammation of the claws and / or the udder.
- pathological changes in the area of cattle claws have become a particularly burdensome economic factor for cattle farms.
- inflammatory changes in the claw skin which usually begin harmlessly, increase at different rates into the depth of the tissue or the claw structures with fatal consequences. This leads to great losses, especially in the dairy industry.
- the Mortellaro disease is a calculus of toe skin, in which a variety of bacteria is found in the affected claws.
- Treponema denticola and Treponema brennaborense from the spirochete genus Treponema are mentioned here.
- Campylobacter faecalis and Bacteroides levii are also found relatively frequently.
- Clinical manifestations include blood oozing, increased horn formation, formation of black pigmented crusts, very long, protruding hair and increased sole horn growth. Chronically, by decreasing the horn quality, a change in shape of the claw shoe, a rupture of the horn and platelet formation occur, which can lead to further serious claw diseases, for example ulcers.
- a pharmaceutical composition according to the invention enables an equally effective treatment of claws or skin diseases, in particular bacterial diseases, and more particularly of Mortellaro disease in cattle.
- the use of antibiotics can advantageously be dispensed with.
- the use of the pharmaceutical composition according to the invention enables easy and low-risk application of an environmentally friendly product of simultaneous good action.
- the pharmaceutical composition can be used in particular as a spray or ointment. It was found that the pharmaceutical composition according to the invention adheres particularly well to the coat of the animals. In addition, the pharmaceutical composition according to the invention is biodegradable and leaves residues in the barn still on pasture.
- the pharmaceutical composition according to the invention can also be used for the treatment of diseases of the udder, in particular for the treatment of udder burning.
- Udder brandy often arises in the context of Mortellaro.
- Uterine gangrene is a progressive necrotic decomposition of udder tissue.
- the main pathogens of the udder band are Clostridium septicum and Staphylococcus aureus.
- the pharmaceutical composition according to the invention can also be used in the treatment of modifiers, in particular in sheep, the causative agent of the fungi is primarily Fusobacterium necrophorum and Dichelobacter nodosus. They lead to a purulent inflammation of the claws.
- the pharmaceutical composition for use in treating claw diseases or udder diseases in animals may contain an unsaturated fatty acid or derivative thereof or contain a vegetable oil wherein the unsaturated fatty acid or derivative thereof or the vegetable oil is oxygenated, in particular ozonated.
- Preferred embodiments of the pharmaceutical composition for use in the treatment of claw diseases or udder diseases in animals are apparent from the preferred embodiments for the general pharmaceutical composition described above.
- the pharmaceutical composition for use in the treatment of claw diseases or udder diseases in animals that it contains glycerol or glycerol derivative or tertiary butanol.
- the pharmaceutical composition for use in the treatment of claw diseases or udder diseases in animals contains glycerol, paraffinum sub liquidum and / or myrsitic acid propyl ester.
- the pharmaceutical composition for use in the treatment of claw diseases or udder diseases in animals contains glycerol.
- the pharmaceutical composition for use in the treatment of claw diseases or udder diseases in animals contains Paraffinum subliquidum.
- the pharmaceutical composition for use in the treatment of claw diseases or udder diseases in animals contains myrsitic acid propyl ester.
- the pharmaceutical composition for use in the treatment of claw diseases or udder diseases in animals may also be intended to contain paraffin.
- the pharmaceutical composition for use in the treatment of claw diseases or udder diseases in animals may be intended to contain no glycerol or glycerol derivative or tertiary butanol, but the unsaturated fatty acid or derivative thereof or the vegetable oil may be present without further additive , or is mixed with another further additive, in particular an organic solvent, preferably DMSO.
- the additive may be, for example, an alcohol or a fat or an oil. If necessary, the composition can thus be free of DMSO.
- a pharmaceutical composition for use in the treatment of claw diseases or udder diseases in animals containing an unsaturated fatty acid or a derivative thereof, wherein the unsaturated fatty acid is oxygenated, and an organic solvent for the unsaturated fatty acid.
- the pharmaceutical composition for use in the treatment of claw diseases or udder diseases in animals in addition to the at least one oxygen-enriched unsaturated fatty acid, in particular oleic acid, or the at least one oxygen-enriched derivative thereof also contains one for the unsaturated fatty acid or for the derivative suitable solvent.
- the solvent may be, for example, glycerol, a glycerol derivative, methanol and / or dimethyl sulfoxide (DMSO).
- DMSO dimethyl sulfoxide
- the solvent is glycerol or DMSO.
- a pharmaceutical composition for use in the treatment of claw diseases or udder diseases in animals containing oxygenated oleic acid and glycerin, a glycerin derivative or DMSO a pharmaceutical composition for use in the treatment of claw diseases or udder diseases in animals containing oxygenated oleic acid and glycerin, a glycerin derivative or DMSO.
- Dimethyl sulfoxide has anti-inflammatory and analgesic properties. It therefore finds therapeutic use as a percutaneous drug for the treatment of local pain conditions (for example sports injuries or rheumatic complaints). Its special ability is its easy penetration into skin and other cell membranes. It therefore serves as a carrier when used on the skin medicines for the introduction of the actual active ingredients as a so-called transport mediator (also called penetration enhancer, tractor substances). In DMSO dissolved substances are thus easily absorbed by the organism through the skin.
- DMSO is not only suitable as a solvent for oxygen-enriched unsaturated fatty acids, in particular oleic acid, but that the mixture of an oxygen-enriched unsaturated fatty acid, in particular oleic acid, and DMSO, without thinking of the theory being bound leads to synergistic effects.
- DMSO allows the entry of the oxygenated unsaturated fatty acid into bacterial cells and fungal cells, and thus surprisingly, the treatment of intracellular microbes such as chlamydia or borrelia.
- infections with anaerobic bacteria can be treated particularly well.
- an activity against viruses could also be demonstrated. All this can be achieved without the use of antibiotics, the use of which is often undesirable.
- a mixture of oxygen-enriched unsaturated fatty acid and DMSO has an advantageous consistency, which can be incorporated well into desired products, for example medical preparations.
- such a mixture can be stored well and for a long time.
- the consistency can be low-viscosity, in particular less viscous than ozonated vegetable oils from the prior art.
- the pharmaceutical composition for use in the treatment of claw diseases or udder diseases in animals contains the acid-enriched unsaturated fatty acid and the organic solvent in a volume ratio of 1 to 20 to 20 to 1.
- the pharmaceutical contains A composition for use in the treatment of claw diseases or udder diseases in animals, the oxygen-enriched unsaturated fatty acid and the organic solvent in a volume ratio of 1 to 15 to 15 to 1.
- the oxygenated unsaturated fatty acid and the organic solvent are in a volume ratio of 1 to 11 to 11 to 1.
- the pharmaceutical composition is for use in In the treatment of claw diseases or udder diseases in animals, the oxygen-enriched unsaturated fatty acid and the organic solvent in a volume ratio of 1 to 2 to 2 to 1.
- the solvent is DMSO.
- a preferred embodiment of the pharmaceutical composition for use in the treatment of claw diseases or udder diseases in animals contains at least 1 g and at most 20 g of the oxygen-enriched unsaturated fatty acid, in particular oleic acid, per 10 ml of DMSO.
- a particularly preferred embodiment of the pharmaceutical composition for use in the treatment of claw diseases or udder diseases in animals contains 10 grams of the oxygenated unsaturated fatty acid, especially oleic acid, per 10 milliliters of DMSO.
- the medical preparation containing a pharmaceutical composition according to the invention for the treatment of diseases of the claws and udders of animals may in particular be a spray, an ointment, a cream, a paste, a solution, a rinse, a plaster or a bandage.
- the pharmaceutical composition is for the treatment of diseases in animals, in particular of mammals in microencapsulated form.
- the pharmaceutical composition is for the treatment of diseases of the claws and udders of animals in microencapsulated form.
- the pharmaceutical composition according to the invention for the treatment of diseases of the claws and udders of animals and corresponding medical preparations are preferably advantageously provided in microencapsulated form.
- the microencapsulation makes it possible to provide controlled release of the active ingredients while at the same time being easy to apply to the claws, fur and skin of the animals.
- a shell component which is good for the environment and easily biodegradable.
- the active ingredients in microcapsules can be administered orally, for example, together with the feed, whereby a release of the active ingredients in the gastrointestinal tract can take place and a systemic treatment is possible.
- the pharmaceutical composition according to the invention for the treatment of diseases of the claws and udders of animals and corresponding medicinal preparations are preferably combined in an advantageous manner with liposomes.
- the liposomes can thereby enable an offset delivery of the active ingredients, while at the same time good applicability to the claws, fur and skin of the animals.
- the liposomes are good for the environment and easily biodegradable.
- the present invention also relates to the use of pharmaceutical compositions and medical preparations according to the invention for the treatment of diseases of the claws and udders of animals.
- the present invention also relates to a method for the treatment of diseases of the claws and udders of animals, wherein on diseased claws or diseased udder or diseased skin and pelts a pharmaceutical composition according to the invention, for example as a medical preparation according to the invention applied or applied and is then allowed to act.
- a pharmaceutical composition according to the invention for example as a medical preparation according to the invention applied or applied and is then allowed to act.
- it is provided in the method that such a treatment is carried out several times, for example over a period of 1 to 10 days, twice a day.
- Preferred embodiments of the invention can be found in the subclaims. Examples:
- Treatment of Mortellaro Disease in Cattle a) A mixture of ozonated oleic acid and glycerol in a ratio of 1 to 20 was filled into a mistletoe. The mixture was sprayed on claws and udders of cattle suffering from Morcellar disease twice a day. The spraying on the altered claws and skin areas was easily carried out. Visible treatment successes set in after only three days of treatment. The effectiveness was thereby of a Veterinarian rated as good, namely between the most common blue spray and the lincomycin in DMSO also used. b) A mixture of ozonated oleic acid and DMSO in a ratio of 1 to 20 was filled into a spray mist. The mixture was sprayed on claws and udders of cattle suffering from Morcellar disease twice a day. The spraying on the altered claws and skin areas was easily carried out. Visible treatment success also came after three days of treatment.
- Skin compatibility in vitro skin corrosion test, MTT test according to OECD guideline 431 and EU procedures B.40 bis: A mixture of 7.5% ozonated oleic acid in glycerol (test mixture) was used as a model for the EpiDerm TM tissue test system tested the human skin. Distilled water was used as a negative control. The positive control used was an 8M KOH solution. The test tissues were preincubated at 37 ° C and 5% C0 2 for one hour in 6-well plates. Then, either the test mixture, the negative control or the positive control was given to the different test tissues. One series of experiments was carried out with an incubation period of 3 minutes, another series of experiments with an incubation period of one hour.
- test mixture After a three-minute incubation period, the test mixture had a relative absorption value of 82.6%, which is thus above the threshold value of 50%. After one hour of incubation, the test mixture had a relative absorbance value of 88.3%, which is also above the corresponding threshold of 15%.
- An alternative plant protection agent was prepared on the basis of 10 g ozonized oleic acid, 5 g of the phosphorus-containing phosphatidylcholine LIPOID S Sojaphospholipids 75 ® Lipoid, Ludwigshafen, Germany and 50 ml of sodium citrate (300 mM, pH 8).
- compositions were suitable for killing Oomycetes cultured in Petri dishes.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Agronomy & Crop Science (AREA)
- Environmental Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102015001289.4A DE102015001289A1 (en) | 2015-01-29 | 2015-01-29 | Pharmaceutical compositions and pesticides containing oxygenated vegetable oils or fatty acids |
PCT/EP2016/051996 WO2016120478A1 (en) | 2015-01-29 | 2016-01-29 | Pharmaceutical compositions and plant protection agents containing oxygen-enriched vegetable oils or fatty acids |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3250187A1 true EP3250187A1 (en) | 2017-12-06 |
Family
ID=55300489
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16702912.3A Withdrawn EP3250187A1 (en) | 2015-01-29 | 2016-01-29 | Pharmaceutical compositions and plant protection agents containing oxygen-enriched vegetable oils or fatty acids |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP3250187A1 (en) |
DE (1) | DE102015001289A1 (en) |
WO (1) | WO2016120478A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111991385A (en) * | 2020-08-17 | 2020-11-27 | 暨南大学 | Application of palmitoleic acid in inhibiting aquatic pathogenic bacteria |
WO2022186802A1 (en) * | 2021-03-01 | 2022-09-09 | Sabanci Ahmet Uemit | Liposomal ozone nanosolutions |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4451480A (en) * | 1982-04-16 | 1984-05-29 | James Howard Brown | Method of treating acne using ozonized materials |
DE3606735C2 (en) | 1986-03-01 | 1994-11-10 | Haensler J Gmbh | Process for the production of stable ozonized oils from unsaturated vegetable oils |
JP4091653B2 (en) | 1992-08-25 | 2008-05-28 | ジー.ディー.サール、リミテッド、ライアビリティ、カンパニー | N- (alkanoylamino-2-hydroxypropyl) sulfonamides useful as retroviral protease inhibitors |
DE19728608C2 (en) | 1997-07-04 | 1999-07-29 | Siegfried Kwasny | Atmospheric oxygen battery |
DE19932570A1 (en) | 1999-07-13 | 2001-01-18 | Gerhard Steidl | Dental antimicrobial preparation comprises olive and/or castor oil enriched with ozone, releases oxygen to control anerobic bacteria e.g. those causing paradontosis |
DE10157260B4 (en) | 2001-11-22 | 2005-12-15 | Pharmoxid Arznei Gmbh + Co. Kg | Spreadable ointment with ozonides and peroxides of fatty acids or their esters |
DE202004021089U1 (en) | 2004-04-01 | 2006-12-14 | Kaczmarek, André, Dr.med.dent. | Ozone stabilizing olive and castor-oil for the treatment of dental gum inflammation comprises ozonizing non-ozonized vegetable oil e.g. olive oil, suspending for homogenization under pressure |
AR051429A1 (en) * | 2004-04-20 | 2007-01-17 | Stenti De Pirillo Haydee A | OZONIZED PHARMACEUTICAL COMPOSITION AND METHODS TO OBTAIN IT |
ITFE20060031A1 (en) * | 2006-11-06 | 2008-05-07 | Istituto Fitofarmaceutico Euga | PROCEDURE FOR THE PREPARATION OF OZONIZED OIL ACID AND APPLICATION OF THIS PRODUCT WITH A PHARMACOLOGICAL AND COSMETIC PURPOSE |
DE102009034308A1 (en) * | 2009-07-21 | 2011-02-03 | Winkelmann, Wolfgang, Dr. | Medical preparation for the treatment of inflammatory processes |
DE102011013920A1 (en) * | 2011-03-14 | 2012-09-20 | Wolfgang Winkelmann | Medical skin cover for the treatment of skin infections |
DE102012007239A1 (en) | 2012-04-10 | 2013-10-10 | Wolfgang Winkelmann | A pharmaceutical composition containing an oxygenated unsaturated fatty acid and an organic solvent |
-
2015
- 2015-01-29 DE DE102015001289.4A patent/DE102015001289A1/en not_active Withdrawn
-
2016
- 2016-01-29 EP EP16702912.3A patent/EP3250187A1/en not_active Withdrawn
- 2016-01-29 WO PCT/EP2016/051996 patent/WO2016120478A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2016120478A1 (en) | 2016-08-04 |
DE102015001289A1 (en) | 2016-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60308891T2 (en) | NEW COMPLEXES OF POLYHYDROXYALKANIC ACID ESTERS AND NIACINAMIDE | |
DE3752217T2 (en) | Topical antimicrobial drugs | |
DE60105283T2 (en) | COMPOSITIONS CONTAINING MOLECULAR IOD | |
DE69521512T2 (en) | NEW PHARMACEUTICAL PREPARATION FOR PAIN TREATMENT | |
RU2452475C2 (en) | Agent for wounds, burns and infectious inflammatory diseases of skin, appendages and mucous membranes | |
EP1818041A2 (en) | Pharmaceutical and/or cosmetic composition containing an organosiloxane and a phospholipid | |
EP2510912A1 (en) | Medical skin coating for treating dermal infections | |
FI126882B (en) | Microbicidal oil-in-water dispersion | |
DE102009008094A1 (en) | In situ adhesive gel-forming preparations, in particular for topical application to moisturized skin / mucosa | |
US9931366B2 (en) | Topical pharmaceutical bases for wound and scar treatment | |
DE69635298T2 (en) | Use of acetylsalicylic acids for the manufacture of a medicament for the treatment of skin injuries | |
DE112009005131T5 (en) | Topical drug for the treatment of psoriasis | |
DE60033383T2 (en) | USE OF TETRAHYDROCURCUMINOIDS FOR THE REGULATION OF PHYSIOLOGICAL AND PATHOLOGICAL CASES IN THE SKIN AND MUCOSA | |
EP3250187A1 (en) | Pharmaceutical compositions and plant protection agents containing oxygen-enriched vegetable oils or fatty acids | |
DE2316597C3 (en) | Active ingredient-containing preparation suitable for topical application to human or animal tissue | |
EP1196159B1 (en) | Use of tosylchloramide(s) for treating diseases of the skin, mucous membranes, organs and tissues | |
EP1392243B1 (en) | Pharmaceutical composition | |
DE602004011786T2 (en) | TAURIN BROMAMINE FOR THE INHIBITION OF PATHOGENIC BACTERIA AND MUSHROOM GROWTH, AND IN A MICROBICID COMPOSITION | |
EP2836202A1 (en) | Pharmaceutical composition containing an unsaturated fatty acid enriched with oxygen and an organic solvent | |
US20040072789A1 (en) | Veterinary composition for the topical treatment of traumatized or inflamed skin | |
CN109453146B (en) | Pathogenic microorganism resisting composition and preparation method and application thereof | |
EP2386309A1 (en) | Bulbine frutescens gel | |
US9867775B2 (en) | Topical pharmaceutical bases for treating inflammatory disorders | |
WO2019170267A1 (en) | Lithium compounds for controlling mites which feed on parts of the skin of humans or homeothermic animals | |
DE3904674A1 (en) | USE OF A COMBINATION OF ACTIVE SUBSTANCES FOR TREATING RHEUMATIC DISEASES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20170829 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20201112 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20230801 |